Advertisement
Screener

BIOMARIN PHARMACEUTICAL INC (BMRN) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

3.0 / 5 stars · 61/101 Roast Me

BIOMARIN PHARMACEUTICAL INC Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

BIOMARIN PHARMACEUTICAL INC (BMRN) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 3-month period ending 2012-09-30, per its 10-Q filed 2012-10-29.

Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2012-10-29

  • BIOMARIN PHARMACEUTICAL INC share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2012-09-30 was 0.00%.
  • BIOMARIN PHARMACEUTICAL INC share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2012-06-30 was 0.00%.
  • BIOMARIN PHARMACEUTICAL INC share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2012-03-31 was 0.00%.
  • BIOMARIN PHARMACEUTICAL INC share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2011-09-30 was 0.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month
2012-09-300.00%
10-Q · filed 2012-10-29
0.00%
10-Q · filed 2012-10-29
2012-06-300.00%
10-Q · filed 2012-08-02
0.00%
10-Q · filed 2012-08-02
2012-03-310.00%
10-Q · filed 2012-04-30
2011-09-300.00%
10-Q · filed 2012-10-29
0.00%
10-Q · filed 2012-10-29
2011-06-300.00%
10-Q · filed 2012-08-02
0.00%
10-Q · filed 2012-08-02
2011-03-310.00%
10-Q · filed 2012-04-30

Similar stocks

Stock NameCountryMarket CapPE Ratio
MADRIGAL PHARMACEUTICALS, INC. (MDGL)United States$11.859B-38.17
Elanco Animal Health Inc (ELAN)United States$11.177B-61.80
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
Axsome Therapeutics, Inc. (AXSM)United States$10.274B-66.82
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)United States$9.331B-42.28
CYTOKINETICS INC (CYTK)United States$9.130B-11.86
Protagonist Therapeutics, Inc (PTGX)United States$8.883B95.52
TG THERAPEUTICS, INC. (TGTX)United States$8.805B19.05